CD33 and acute myeloid leukemia: For redirection of RevCAR-E5B9-28/3z or RevCAR-E7B6-28/3z T-cells against CD33 or CD123 expressing AML blasts, we have developed four novel RevTMs, named RevTM CD33-5B9, CD123-5B9, CD33-7B6 or CD123-7B6 (Figure 1a,b).